Atea Pharmaceuticals, Inc. (AVIR) Stock Grade

About Atea Pharmaceuticals, Inc.'s fundamentals

Atea Pharmaceuticals is a biotechnology company with a market capitalization of $290.9 million that reported flat revenue growth year-over-year with no net income generation. The company posted a net loss in its latest annual statement and maintains a net margin of 0.0%, indicating it is not yet profitable. With no dividend yield and unavailable profitability ratios, the company's financial performance reflects the typical profile of an early-stage biotech firm focused on research and development rather than current earnings.